The Immunopathology of Lymphoreticular Neoplasms

1. Front Matter

   Pages i-xx

   PDF

2. Development of Lymphoid Tissues

   • Max D. Cooper, Alexander R. Lawton

   Pages 1-21

3. Regulation of the Immune Response

   • Richard K. Gershon, Charles M. Metzler

   Pages 23-51

4. Aging and Involution of the Immunological Apparatus

   • E. J. Yunis, G. Fernandes, Robert A. Good

   Pages 53-80

5. Experimental Models of Lymphoid Malignancies

   • Raymond D. A. Peterson

   Pages 81-127

6. Epidemiology of Primary Neoplasms of Lymphoid Tissues in Animals

   • William D. Hardy Jr.

   Pages 129-180

7. Epidemiology of Lymphoreticular Malignancies in Man

   • Nicholas J. Vianna

   Pages 181-201

8. Immunodeficiency Diseases and Malignancy

   • Beatrice D. Spector, Guy S. Perry III, Robert A. Good, John H. Kersey

   Pages 203-222

9. Immunosuppression and Malignant Disease

   • Israel Penn

   Pages 223-237

10. The Pathology of Lymphoreticular Neoplasms

    • Robert J. Lukes, John W. Parker

    Pages 239-279

11. Cytoidentity of the Lymphoreticular Neoplasms

    • Frederick P. Siegal

    Pages 281-323

12. Ecotaxis, Ecotaxopathy, and Lymphoid Malignancy: Terms, Facts, and Predictions

    • Maria De Sousa

    Pages 325-359

13. Immunoglobulins in the Normal State and in Neoplasms of B Cells

    • Edward C. Franklin, Joel Buxbaum

    Pages 361-390

14. Burkitt’s Lymphoma and Infectious Mononucleosis

    • Dennis H. Wright

    Pages 391-424

15. α–Chain Disease: A Possible Model for the Pathogenesis of Human Lymphomas

    • Maxime Seligmann, Jean-Claude Rambaud

    Pages 425-447

16. Lymphoreticular Disorders of the Gastrointestinal Tract: Roentgenographic Features

    • Richard H. Marshak, Arthur E. Lindner, Daniel Maklansky

    Pages 449-491

17. Proliferative Disorders of the T-Cell Series

    • Bijan Safai

    Pages 493-532

18. Lymphoreticular Malignancies in Childhood

    • John H. Kersey, Mark E. Nesbit

    Pages 533-542

19. Immunodeficiency States Associated with Acute Leukemias, Multiple Myeloma, and Waldenström’s Macroglobulinemia

    • Benjamin Koziner, Robert A. Good

    Pages 543-564

20. Immunodeficiencies Associated with Chronic Lymphocytic Leukemia and Non–Hodgkin’s Lymphomas

    • Sudhir Gupta, Robert A. Good

    Pages 565-583

Until recently, understanding of the lymphomas was limited and largely descriptive. Attention has been focused, for the most part, upon morphological issues and clinical matters. Although useful, this approach has many shortcomings. The true cytoidentity of primary neoplastic cells was not established by these methods, nor could their clonal nature be recognized. The more overt changes in immunological function, such as monoclonal gammopathies and immunodeficiencies, were appre­ ciated as important components of these diseases. However, subtle immunological perturbations were not recognized. Furthermore, associations were not established between the lymphoreticular neoplasms on the one hand and both primary and secondary immunological abnormalities on the other. There has been considerable recent progress in the fields of immunobiology, cytology, and immunochemistry. These new approaches have proved readily applicable to studies on the lymphomas. The term "lymphoma" has been applied to a heterogeneous group of neo­ plasms that involve lymphoid tissues. This term is not altogether satisfactory, since it implies that cells of primarily the lymphoid series are involved in the neoplastic process. Some neoplasms, heretofore classified as "lymphomas," now appear, from the results of penetrating analysis using newer methodology, to be malignan­ cies of the macrophage series, rather than of the lymphocytic series. These neo­ plasms include Hodgkin's disease and a minority of neoplasms previously referred to as "histiocytic" lymphomas. The majority of these "histiocytic" lymphomas are now known to be lymphoid malignancies involving the B-cell series.

• diseases
• immunobiology
• pathology

• Veterans Administration Hospital, Houston, USA

  J. J. Twomey

• Sloan-Kettering Institute for Cancer Research, New York, USA

  Robert A. Good

Policies and ethics